Trial Profile
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms onset8
- Sponsors Novo Nordisk
- 01 Jun 2019 Post hoc analysis of Onset 1 and Onset 8 trial published in the Diabetes Therapy.
- 05 Oct 2018 Results of post hoc analysis of onset 8 study assessing the impact of dose adjustment methodology (DAM) in relation to the efficacy and safety of mealtime faster aspart in T1D. presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 30 Aug 2018 Primary endpoint has been met. (Change from baseline in HbA1c after 26 weeks of treatment) as per results published in the European Clinical Trials Database Trial Registry